Acquired von willebrand disease: Correction of hemostatic defect by high‐dose intravenous immunoglobulins | Zendy

Delmer A. | Zendy; Horellou M. H. | Zendy; Bréchot J. M. | Zendy; Prudent J. | Zendy; Potevin F. | Zendy; Lecrubier C. | Zendy; GirardLonghini C. | Zendy; Samama M. | Zendy; Zittoun R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Acquired von willebrand disease: Correction of hemostatic defect by high‐dose intravenous immunoglobulins

Author(s) -

Delmer A.,

Horellou M. H.,

Bréchot J. M.,

Prudent J.,

Potevin F.,

Lecrubier C.,

GirardLonghini C.,

Samama M.,

Zittoun R.

Publication year - 1992

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.2830400214

Subject(s) - medicine , von willebrand factor , von willebrand disease , antibody , hemostasis , intravenous immunoglobulins , gastroenterology , surgery , immunology , platelet

High‐dose intravenous immunoglobulins (ivIG) were used in a 57‐year‐old patient with acquired von Willebrand disease in order to correct a hemostatic defect before pneumonectomy for lung carcinoma. IvIG induced a rapid and complete correction of factor VIII (F VIII) and von Willebrand factor (vWF) and allowed surgery without additional factor coverage. F VIII and vWF returned to baseline values within 10 days after ivIG. © 1992 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research